Critical Outcome Technologies Inc.
Records under this name other than the patents Critical Outcome Technologies Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
Back to Critical Outcome Technologies Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,895,556 | Compounds and method for treatment of cancer Lapsed on the fee record Ended Nov 25, 2022 · USPTO record | Lapsed on the fee record | Ended Nov 25, 2022 | USPTO record |
| US 8,822,475 | Compounds and method for treatment of cancer Lapsed on the fee record Ended Sep 2, 2022 · USPTO record | Lapsed on the fee record | Ended Sep 2, 2022 | USPTO record |
| US 7,629,347 | Protein tyrosine kinase inhibitors Formerly held Lapsed on the fee record Ended Dec 8, 2021 · USPTO record | Lapsed on the fee record | Ended Dec 8, 2021 | USPTO record |
| US 8,580,792 | Inhibitor compounds and cancer treatment methods Lapsed on the fee record Ended Nov 12, 2021 · USPTO record | Lapsed on the fee record | Ended Nov 12, 2021 | USPTO record |
| US 7,585,866 | Protein tyrosine kinase inhibitors Lapsed on the fee record Ended Sep 8, 2021 · USPTO record | Lapsed on the fee record | Ended Sep 8, 2021 | USPTO record |
| US 8,466,151 | Compounds and method for treatment of cancer Lapsed on the fee record Ended Jun 18, 2021 · USPTO record | Lapsed on the fee record | Ended Jun 18, 2021 | USPTO record |
| US 9,624,220 | Compounds and method for treatment of HIV Lapsed on the fee record Ended Apr 18, 2021 · USPTO record | Lapsed on the fee record | Ended Apr 18, 2021 | USPTO record |
| US 8,420,643 | Compounds and method for treatment of cancer Lapsed on the fee record Ended Apr 16, 2021 · USPTO record | Lapsed on the fee record | Ended Apr 16, 2021 | USPTO record |
| US 8,367,675 | Compounds and method for treatment of cancer Formerly held Lapsed on the fee record Ended Feb 5, 2021 · USPTO record | Lapsed on the fee record | Ended Feb 5, 2021 | USPTO record |
| US 8,252,800 | Protein tyrosine kinase inhibitors Lapsed on the fee record Ended Aug 28, 2020 · USPTO record | Lapsed on the fee record | Ended Aug 28, 2020 | USPTO record |